Division of Anesthesia Critical Care, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USAUnited States
Division of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USAUnited States
Division of Cardiothoracic Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USAUnited States
Also available as PDF (figures and tables appear in the PDF).
Introduction: Gastric acid aspiration into the lung has long been established as a direct cause of acute lung injury that rapidly leads to a clinical diagnosis of acute respiratory distress syndrome (ARDS). Gastric juices contain a low pH liquid and frequently mouth organisms. When aspiration of gastric liquid into the lower airway occurs, a caustic injury to the lower airway and distal airspaces occurs. The acute inflammatory events that occur following gastric acid aspiration induce injury by direct lung tissue toxicity.1 As well, acute adhesion of activated blood neutrophils throughout the pulmonary microcirculation and the subsequent migration of activated cells into the alveolar space rapidly induces acute injury to the alveolar capillary membrane with subsequent rapid loss of lung barrier function. Virtually always acute lung injury of the magnitude described in the case we report here occurs, producing ARDS. Thus far, no therapy has reliably proven effective for gastric acid-induced ARDS. Case Presentation: In this report, we describe the onset of acute respiratory failure with rapid onset ARDS in a 34-year-old patient who experienced a generalized tonicclonic seizure followed by witnessed vomiting and aspiration of gastric contents following a morning meal. The patient rapidly developed acute respiratory failure, necessitating mechanical ventilation. Ventilatory support failed to oxygenate or ventilate the patient. Extracorporeal membrane oxygenation was instituted. Vitamin C was infused intravenously at 50 mg/kg every 6 hours starting on hospital day 2 with subsequent significant improvement in lung function and lung imaging. Conclusion: This report adds to the increasing clinical experience employing high dosages of intravenous vitamin C to attenuate the acute inflammatory lung injury. If further adds to the experience of using extracorporeal membrane oxygenation to support lung injured patients.
Keywords: Intravenous vitamin C; Acute respiratory distress syndrome; Extracorporeal membrane oxygenation; Acute respiratory failure; Gastric acid aspiration
No effective therapy has previously been described for gastric acid-induced ARDS. High dosage intravenous vitamin C as described in this report and other reports from Virginia Commonwealth University Richmond, VA, USA, have proven to be effective adjunctive anti-inflammatory therapies. We report here the first application of high dose intravenous vitamin C employed as an interventional drug therapy for gastric acid-induced ARDS.
The use of intravenous vitamin C to treat acute lung injury is still investigational and is the subject of an ongoing NIH-funded double-blinded placebo-controlled multicenter trial, examining its use in sepsis-induced ARDS. Few studies have reported the use of intravenous vitamin C in critically ill patients with ARDS. Sawyer et al2 reported that large intravenous doses of ascorbic acid plus other antioxidants (i.e., tocopherol, N-acetyl-cysteine, selenium), in patients with ARDS reduced mortality by 50%. Nathens and colleagues infused ascorbic acid intravenously at 1 gram every 8 hours co-administered with oral vitamin E for 28 days in 594 surgically critically ill patients.3 They found a lower incidence of multiple organ failure and acute lung injury. Tanaka and colleagues infused ascorbic acid at a dosage of 66 mg/kg/ hour for the first 24 hours in patients suffering greater than 50% surface area burns and showed significantly reduced thermal injury-induced capillary permeability with significantly lower intravenous volume required for resuscitation.4 Increasing plasma ascorbic acid levels in hospitalized patients following gastric acid-induced ARDS is not part of current critical care practice. Vitamin C dosages utilized in the treatment of the patient we describe in this case report of gastric acid-induced ARDS arose
Figure 3. Computed Tomographic Imaging of the Chest Hospital Day 6, ECMO Day 6 Reveals Significant Resolution of Pulmonary Edema and Airspace Opacities.
from our previous human studies where we infused high doses intravenous vitamin C into critically ill patients with severe 5 6-8 sepsis5 and in our preclinical animal studies.6-8 Our preclinical studies clearly show that vitamin C exerts robust “pleiotropic effects” when utilized as reported in the care of this patient with gastric acid-induced ARDS. In a recent study in critically ill patients with severe sepsis, we infused vitamin C at 50 mg/kg every 6 hours and found a marked reduction in multiple organ injury with reduced inflammatory biomarker levels in plasma.5 Our preclinical work in septic, lung-injured animals, shows that vitamin C down-regulates pro-inflammatory genes driven by transcription factor NF-κB.7 Early work by Kennedy et al and Goldman et al previously established that pulmonary gastric acid aspiration promotes an “acid burn” in lung, leading to rapid loss of lung barrier function as activated neutrophils migrate into the airspaces, producing tissue injury by liberating reactive oxygen species and proteolytic enzymes.9,10 As a consequence, following acid aspiration, pulmonary edema forms rapidly as we report here with the acute onset of respiratory failure. Our prior research with vitamin C has revealed that parenteral infusion of vitamin C significantly increases alveolar fluid clearance in septic lung-injured animals.8 Further, our research shows that vitamin C down-regulates neutrophil extracellular trap formation, a newly described phenomenon where circulating blood neutrophils exposed to certain pro-inflammatory stimuli disgorge their genomic DNA into their peri-cellular space. Extracellular DNA from the neutrophil contains adherent lysosomal enzymes which remain active and capable of damaging lung microcirculation, thus leading to pulmonary capillary damage. Infused vitamin C is also capable of dismuting liberated reactive oxygen and nitrogen species which also appears necessary for attenuating lung injury.
Prior reports have described ARDS with such severity that ECMO was required. Wetsch et al described a 39-year-old man who sustained massive gastric acid aspiration with resultant ARDS who was supported with ECMO.14 During the hospital course of the patient we report here, short-term methyl prednisolone was also infused and likely played an undetermined role in promoting resolution of the patient’s lung injury. Zhao et al15 recently reported a retrospective analysis of 73 acute stroke patients who were diagnosed with aspiration-related ARDS and in whom the hospital mortality rate was 39.7%. Short-term corticosteroids reported in Zhao’s study were administered in 47 patients (64.4 %) at a mean dosage of 1.14 mg/kg per day of methylprednisolone via intravenous infusion for a period of 7.3 days. Ground glass opacities reported in chest computed tomography images in Zhao’s study improved when corticosteroids were administered. However, none of the ARDS patients Zhao reported sustained the extent of lung injury similar to the patient we describe here and none were treated with extracorporeal membrane oxygenation.
In summary, we describe the first utilization of high dose, intra-
venously infused, vitamin C in the treatment of severe gastric acid-induced ARDS. Both extensive preclinical work and as well as human studies thus far, examining parenterally administered vitamin C, leads us to conclude that this new form of therapy may become a useful adjunct in the care of patients with acute lung injury. The use of intravenous vitamin C is slowly emerging as a potentially effective adjunctive therapy for ARDS secondary to multiple etiologies (i.e., bacterial and viral infection). Bharara et al previously described the use of intravenous vitamin C as adjunctive therapy in a young woman with recurrent sepsis-induced ARDS,16 while Fowler et al reported intravenous vitamin C infusion in a patient who developed ARDS secondary to enterovirus/rhinovirus-induced ARDS.17 The current case 16,17 report and the two reports cited here along with the phase II NIH-supported multi-center trial, examining intravenous vitamin C’s role as therapy in sepsis-induced ARDS will begin to 9,10 shape the usage of vitamin C as a new standard of care therapy. As has been established for decades now, ARDS can occur secondary to many lung insults. In the current report, intravenous vitamin C was employed in a patient with who developed ARDS secondary to massive gastric acid aspiration.
11 Ethics approval and consent to participate: This study was approved by the Virginia Commonwealth University Institutional Review Board (IRB). The IRB approval number assigned to this 12 trial was: HM12903.
Consent for publication: Consent for publication was given by the patient. Data for this report was de-identified and confidentiality maintained.
The authors acknowledge the superior care provided by the VCU Cardiothoracic Nursing service for their amazing nursing care which assured a good outcome to this patient’s care.
The authors declare no financial or non-financial competing interests.
Data for this case report was extracted from the patient’s electronic medical record and the VCU Radiology Imaging Service. The dataset generated and analyzed during the current study are not publicly available due to the fact that individual privacy could be compromised. The authors feel it essential that privacy not be compromised. We assure the material reported here be kept confidential to maintain that privacy. Thus, the data is NOT publically available due to confidentiality reasons.
- Christin Kim, MD: Clinical Critical Care of the patient, ECMO clinician, manuscript drafting, editing; - Orlando Debesa, DO: Clinical Critical Care of the patient, ECMO clinician, manuscript drafting, editing; - Patricia Nicolato, DO: Clinical Critical Care of the patient, Thoracic Surgeon who inserted ECMO, manuscript drafting, editing - Bernard Fisher, MS: Vitamin C scientist, manuscript drafting, editing; - Ramesh Natarajan, PhD: Vitamin C scientist, manuscript drafting, editing; - Alpha A. Fowler, III, MD: Vitamin C scientist, manuscript Author.
National Institutes of Health, 5UM1HL116885-02, The Aubrey Sage Macfarlane Lung Injury Research Fund (a philanthropic fund gifted to the VCU Johnson Center for Critical Care and Pulmonary Research).
We additionally acknowledge the amazing care provided by the intensive care unit Nursing staff who cared for the patient in the Cardiac Surgery Intensive Care Unit at Virginia Commonwealth University.
Trial registry: Clinical Trials.gov; https://clinicaltrials.gov/ct2/ show/NCT02106975?term=citris-ali&rank=1, Trial Registration Number: NCT02106975, Date of Registration: March 27, st 2014, Date of 1st enrollment: 9-15-14.